Promotion of cutaneous diabetic wound healing by subcutaneous administration of Wharton's jelly mesenchymal stem cells derived from umbilical cord

Nilforoushzadeh, Mohammad Ali; Raoofi, Amir; Afzali, Hamideh; Gholami, Omid; Zare, Samad; Nasiry, Davood; Darian, Ebrahim Khodaverdi; Rustamzadeh, Auob; Alavi, Shiva; Ahmadi, Rahim; Alimohammadi, Alimohammad; Razzaghi, Zahra; Naraghi, Z Safaei; Mahmoudbeyk, Mona; Amirkhani, Mohammad Amir; Khaneghah, Amin Mousavi

doi:10.1007/s00403-022-02326-2

Cited by 21 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collagen is one of the main structures of the ECM and determines the consistency of tissue [44]. These fibers are produced by fibroblasts in the dermis, however, during diabetes their production and quality are significantly reduced [9]. However, our hypothesis was that the use of Juglans regia L. leaf extract, as a strong antioxidant, can increase collagen production by controlling oxidative stress in fibroblast cells.…”

Section: Discussionmentioning

confidence: 89%

“…The next reason is the weakness of local cells such as fibroblasts and keratinocytes due to oxidative stress caused by systemic hyperglycemia in the production of some cytokines effective in repair and regeneration such as transforming growth factor (TGF)-β and insulin-like growth factor (IGF)-1 [7,8]. Also, due to the weakness of fibroblast cells, the production of collagen fibers as the most important compound in the extracellular matrix (ECM) faces a serious problem and the closing time is delayed [9]. Moreover, due to the inappropriate quality of the produced collagens, even if the diabetic wound heals, it does not have ideal biomechanical properties and after some time, the wound will form again [10].…”

Section: Open Accessmentioning

confidence: 99%

See 1 more Smart Citation

Topical administration of Juglans regia L. leaf extract accelerates diabetic wound healing

Nasiry

Khalatbary

Ghaemi

et al. 2022

BMC Complement Med Ther

Self Cite

View full text Add to dashboard Cite

Background Diabetic wounds are one of the most important issues in diabetic patients. It seems that Juglans regia L. leaf with antioxidant and anti-inflammatory potentials can be profitable for healing of diabetic wounds. The aim of present study was to investigate the topical administration of Juglans regia L. leaf extract in diabetic wound healing. Methods Seventy-five diabetic male rats were randomly divided into 5 groups (n = 15), including: untreated (Control) group, Eucerin group, 2% Juglans regia L. ointment (JRL 2%) group, 5% Juglans regia L. ointment (JRL 5%) group, and Phenytoin group as a reference drug. Sampling was performed at days 7, 14, and 21 after surgery. Evaluation tests included stereology, immunohistochemistry, molecular, and biomechanical. Results Our results showed that the wound closure rate, volumes of newly formed of epidermis and dermis, density of fibroblasts and blood vessels, collagen deposition, density of proliferation cells, expression levels of TGF-β and VEGF genes, and biomechanical characteristics were significantly higher in extract groups compared to control and eucerin groups, however, these changes were considerable in the JRL 5% group (P < 0.05). This is while that the density of neutrophils and expression levels of TNF-α and IL-1β genes in the extract groups, especially in the JRL 5% group, were significantly reduced compared to control and eucerin groups (P < 0.05). Conclusion Topical administration of Juglans regia L. leaf extract, especially in 5% concentration, considerably accelerates diabetic wound healing.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Open Accessmentioning

confidence: 99%

Topical administration of Juglans regia L. leaf extract accelerates diabetic wound healing

Nasiry

Khalatbary

Ghaemi

et al. 2022

BMC Complement Med Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…The sample was then centrifuged (1750 RPM, 7min), and the cell plate was placed in Dulbecco's Modified Eagle Medium (DMEM) with glucose concentration 1000 mg/L (Gibco, UK) containing 10% FBS to be later cultured in a 25 cm2 flask. Trypsin (0.25%, Gibco, UK) was used for cell passage, 10% froze Dimethyl sulfoxide (DMSO) and 90% FBS were used for long‐term storage of cells 16 …”

Section: Methodsmentioning

confidence: 99%

Topical spray of Wharton's jelly mesenchymal stem cells derived from umbilical cord accelerates diabetic wound healing

Nilforoushzadeh

Afzali

Raoofi

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background and Aim: Cell-based therapy utilizing mesenchymal stem cells (MSCs) is currently being investigated as a therapeutic agent for chronic wounds. There is no evidence regarding effectiveness of the spray and local transfer of this cellular product in diabetic wound healing. Accordingly, the present study, using clinical, pathological and biometric parameters, investigated the effectiveness of the spray of these cells in the healing of diabetic wounds in rats.Methods: Three days after the induction of diabetes (50 mg/kg single dose of streptozotocin) a circular excision was created on the back of rats. Diabetic rats were divided into two groups (n = 21): Control and WJ-MSCs group. Sampling of the studied groups was performed on Days 7, 14, and 21 after wounding. Histological, ultrasound imaging of dermis and epidermis in the wound area for thickness and density measurement and skin elasticity were evaluated.Results: Our results on Days 7, 14, and 21 after wounding showed that the wound closure, thickness, and density of new epidermis and dermis, as well as skin elasticity

show abstract

“…Besides being easily accessible and numerous, WJ-MSCs show features of embryonic stem cells (ESCs) in terms of proliferation, multipotency and low immunogenicity, but do not form teratomas upon transplantation as ESCs do and there are not ethical limitations in their use ( Liau et al, 2020 ). WJ-MSCs also proved to efficiently promote diabetic wound healing in preclinical studies ( Jiao et al, 2021 ; Nilforoushzadeh et al, 2022 ). Other MSCs that got attention for their ability to promote diabetic wound healing are those obtained from the placenta (Pl-MSCs) or the amniotic fluid (AF-MSCs) ( Kim et al, 2012 ; Kong et al, 2013 ; Lee et al, 2015 ; Wu et al, 2017 ) ( Figure 1 ).…”

Section: Innovative Therapies For Diabetic Foot Ulcersmentioning

confidence: 99%

Innovative Cell and Platelet Rich Plasma Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic Approach

Mastrogiacomo

Nardini

Collina

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cutaneous chronic wounds are a major global health burden in continuous growth, because of population aging and the higher incidence of chronic diseases, such as diabetes. Different treatments have been proposed: biological, surgical, and physical. However, most of these treatments are palliative and none of them can be considered fully satisfactory. During a spontaneous wound healing, endogenous regeneration mechanisms and resident cell activity are triggered by the released platelet content. Activated stem and progenitor cells are key factors for ulcer healing, and they can be either recruited to the wound site from the tissue itself (resident cells) or from elsewhere. Transplant of skin substitutes, and of stem cells derived from tissues such as bone marrow or adipose tissue, together with platelet-rich plasma (PRP) treatments have been proposed as therapeutic options, and they represent the today most promising tools to promote ulcer healing in diabetes. Although stem cells can directly participate to skin repair, they primarily contribute to the tissue remodeling by releasing biomolecules and microvesicles able to stimulate the endogenous regeneration mechanisms. Stem cells and PRP can be obtained from patients as autologous preparations. However, in the diabetic condition, poor cell number, reduced cell activity or impaired PRP efficacy may limit their use. Administration of allogeneic preparations from healthy and/or younger donors is regarded with increasing interest to overcome such limitation. This review summarizes the results obtained when these innovative treatments were adopted in preclinical animal models of diabetes and in diabetic patients, with a focus on allogeneic preparations.

show abstract

Promotion of cutaneous diabetic wound healing by subcutaneous administration of Wharton's jelly mesenchymal stem cells derived from umbilical cord

Cited by 21 publications

References 37 publications

Topical administration of Juglans regia L. leaf extract accelerates diabetic wound healing

Topical administration of Juglans regia L. leaf extract accelerates diabetic wound healing

Topical spray of Wharton's jelly mesenchymal stem cells derived from umbilical cord accelerates diabetic wound healing

Innovative Cell and Platelet Rich Plasma Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic Approach

Contact Info

Product

Resources

About